Senseonics Holdings, Inc. (NYSE:SENS), a leading diabetes management company, witnessed a significant surge in its stock price, soaring 5.44% in the pre-market trading session on Monday. This rally in Senseonics' shares can be attributed to the company's recent success with its flagship product, Eversense 365, and its ambitious growth plans for the upcoming year.
In the third quarter of 2024, Senseonics achieved a major milestone by obtaining FDA approval and launching Eversense 365, the world's first 365-day continuous glucose monitoring (CGM) system. This groundbreaking product garnered remarkable success, with the company reporting increased patient shipments, a rise in prescribing providers, and a significant surge in prescriptions from top prescribers.
Building on this momentum, Senseonics has set ambitious goals for 2024. The company plans to double its patient starts in the US market and expand its global footprint by an impressive 50%. To achieve these objectives, Senseonics will focus on product development, establishing strategic healthcare partnerships, and the international launch of the Eversense 365 system.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。